Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20330477 | 0.90 | KDM4E (0.36) | KDM4EALDH1A1CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL24856105 | 0.85 | KDM4E (0.43) | KDM4EALDH1A1CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL20206305 | 0.85 | KDM4E (0.43) | KDM4EALDH1A1CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL25122859 | 0.85 | KDM4E (0.43) | KDM4EALDH1A1CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL24897599 | 0.83 | CYP2C19 (0.49) | KDM4EALDH1A1CES2NPSR1CYP2C19 | |
| SCHEMBL24654423 | 0.83 | CES2 (0.56) | KDM4EALDH1A1CES2NPSR1CYP2C19 | |
| SCHEMBL22374683 | 0.83 | MEN1 (0.33) | KDM4EALDH1A1CES2CYP2C19EPHX2 | |
| SCHEMBL21664802 | 0.81 | KDM4E (0.40) | KDM4EALDH1A1CES2NPSR1CYP2C19 | |
| SCHEMBL19599821 | 0.81 | KDM4E (0.40) | KDM4EALDH1A1CES2NPSR1CYP2C19 | |
| SCHEMBL22006738 | 0.81 | CES2 (0.40) | KDM4ECES2CYP2C19EPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | KDM4E 1071/4885ALDH1A1 2896/4885CES2 4048/4885 |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | KDM4E 1071/4885ALDH1A1 2896/4885CES2 4048/4885 |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | KDM4E 2053/4885ALDH1A1 2958/4885CES2 3114/4885 |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | KDM4E 3016/4885ALDH1A1 4188/4885CES2 2984/4885 |
| US-11666661-B2 | Methods and compounds for targeted autophagy | ATG7, BECN1, SQSTM1 | KDM4E 3016/4885ALDH1A1 4188/4885CES2 2984/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | KDM4E 2053/4885ALDH1A1 2958/4885CES2 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.